Literature DB >> 31588916

Effects of nicorandil on vascular and renal dysfunctions in adenine-induced nephropathy: Possible underlying mechanisms.

Abdelaziz M Hussein1, Mohamed Eldosoky, Hala Abdel Malek, Mohamed Elshafey, Eman El Nashar, Gamal Dahab.   

Abstract

Vascular dysfunctions in chronic kidney disease (CKD) include endothelial dysfunctions and vascular calcification (VC). In the present study, we examined the possible protective effect of nicorandil (potassium channel opener) on renal and vascular dysfunctions in a rat model of adenine-induced nephropathy and its underlying mechanisms. Thirty-four male Sprague-Dawley rats were randomly allocated into 3 groups: Control group, Adenine group (animals received high-adenine diet for 4 weeks), and Nicorandil group (animals received adenine for 4 weeks and nicorandil 1 mg/kg per oral for 4 weeks). The results showed significant reduction in the body weight, heart rate (HR), hemoglobin contents, serum Ca2+ and reduction in the expression of mRNA of endothelial nitric oxide synthase (eNOS) and nuclear factor erythroid related factor 2 (nrf2) genes in aortic tissues with significant increase in arterial blood pressure (ABP), serum creatinine, blood urea nitrogen (BUN), plasma renin activity (PRA), K+ and phosphate (PO43-), urinary albumin excretion (UAE) and aortic VC in Adenine group compared to normal group (p < 0.05). On the other hand, coadminsitration of nicorandil caused significant improvement in the studied parameters compared to Adenine group (p < 0.05). We concluded that nicorandil has a potential protective effect against the vascular and renal impairment induced by adenine, which might be due to attenuation of vascular calcifications, activation of Nrf2 and eNOS genes in aortic tissues.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31588916     DOI: 10.4149/gpb_2019034

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  3 in total

1.  Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.

Authors:  Xiaozhi Du; Zhiyong Ma; Li Li; Xuezhen Zhong
Journal:  J Cardiovasc Pharmacol       Date:  2021-09-29       Impact factor: 3.105

Review 2.  Folic acid-induced animal model of kidney disease.

Authors:  Liang-Jun Yan
Journal:  Animal Model Exp Med       Date:  2021-11-24

3.  Harmful and Beneficial Role of ROS 2020.

Authors:  Sergio Di Meo; Paola Venditti; Victor M Victor; Gaetana Napolitano
Journal:  Oxid Med Cell Longev       Date:  2022-07-22       Impact factor: 7.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.